Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)
Acute Respiratory Distress Syndrome
About this trial
This is an interventional basic science trial for Acute Respiratory Distress Syndrome focused on measuring ARDS, endothelium, CNP, Acute lung injury
Eligibility Criteria
Inclusion Criteria: Healthy male and female volunteers BMI of 18-40 kg/m2 Aged 18-45 Volunteers who are willing to sign the consent form Exclusion Criteria: Healthy subjects unwilling to consent Smokers Known sensitivity to Racecadotril History of any serious illnesses, including recent infections or trauma A personal history of keloid scarring, or a family history of keloid scarring in a first degree relative with similar skin pigmentation Subjects taking systemic medication (other than the oral contraceptive pill) Subjects who are pregnant or any possibility that a subject may be pregnant, unless in the latter case a pregnancy test is performed with a negative result Women who are breastfeeding Subjects with recent or current antibiotic use Subjects with a history of skins conditions. Subjects with a history of allergic reaction to any topical application or history of angioedema Subjects with any history of a blood-borne infectious disease such Hepatitis B or C virus, or HIV.
Sites / Locations
- William Harvey Research Institute- Heart CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo
Racecadotril
Placebo tablet to be taken three times a day for three days
Racecadotril 100 milligrams (mg) three times a day for three days